Laparoscopic Uterosacral Nerve Ablation for Alleviating Chronic Pelvic Pain
A Randomized Controlled Trial

Jane Daniels, MSc
Richard Gray, MSc
Robert K. Hills, PhD
Pallavi Latthe, MD
Laura Buckley, PhD
Janesh Gupta, MD, MSc
Tara Selman, PhD
Elizabeth Adey, BSc
Tengbin Xiong, PhD
Rita Champaneria, MPhil
Richard Lilford, PhD
Khalid S. Khan, MD, MSc
on behalf of the LUNA Trial Collaboration

Context  Chronic pelvic pain is a common condition with a major effect on health-related quality of life, work productivity, and health care use. Operative interruption of nerve trunks in the uterosacral ligaments by laparoscopic uterosacral nerve ablation (LUNA) is a treatment option for patients with chronic pelvic pain.

Objective  To assess the effectiveness of LUNA in patients with chronic pelvic pain.

Design, Setting, and Participants  Randomized controlled trial of 487 women with chronic pelvic pain lasting longer than 6 months without or with minimal endometriosis, adhesions, or pelvic inflammatory disease, who were recruited to the study by consultant gynecological surgeons from 18 UK hospitals between February 1998 and December 2005. Follow-up was conducted by questionnaires mailed at 3 and 6 months and at 1, 2, 3, and 5 years.

Intervention  Bilateral LUNA or laparoscopy without pelvic denervation (no LUNA); participants were blinded to the treatment allocation.

Main Outcome Measures  The primary outcome was pain, which was assessed by a visual analogue scale. Data concerning the 3 types of pain (noncyclical pain, dysmenorrhea, and dyspareunia) were analyzed separately as was the worst pain level experienced from any of these 3 types of pain. The secondary outcome was health-related quality of life, which was measured using a generic instrument (EuroQoL EQ-5D and EQ-VAS).

Results  After a median follow-up of 69 months, there were no significant differences reported on the visual analogue pain scales for the worst pain (mean difference between the LUNA group and the no LUNA group, −0.04 cm [95% confidence interval (CI), −0.33 to 0.25 cm]; P = .80), noncyclical pain (−0.11 cm [95% CI, −0.50 to 0.29 cm]; P = .60), dysmenorrhea (−0.09 cm [95% CI, −0.49 to 0.30 cm]; P = .60), or dyspareunia (0.18 cm [95% CI, −0.22 to 0.62 cm]; P = .40). No differences were observed between the LUNA group and the no LUNA group for quality of life.

Conclusion  Among women with chronic pelvic pain, LUNA did not result in improvements in pain, dysmenorrhea, dyspareunia, or quality of life compared with laparoscopy without pelvic denervation.

Trial Registration  controlled-trials.com Identifier: ISRCTN41196151

©2009 American Medical Association. All rights reserved.
assurance and relief to some patients but in the absence of underlying pathology, no established gynecological treatments are available.

Nerve plexuses and parasympathetic ganglia in the uterosacral ligaments are thought to carry pain signals from the uterus, cervix, and other pelvic structures. Conventional open vaginal and abdominal procedures have been used to interrupt these nerve trunks by dividing the attachments of the uterosacral ligaments to the cervix in women with dysmenorrhea. In part because these procedures are invasive and carry risk and their efficacy has not been established, they have not been widely adopted. Laparoscopic uterosacral nerve ablation (LUNA) is performed after diagnostic laparoscopy and can be completed using lasers or electrosurgery and has become increasingly used. Systematic reviews of the current research evidence on LUNA’s efficacy are inconclusive. A National Institute of Clinical Excellence report suggested that there was not sufficient evidence of its value. Clinicians’ beliefs about LUNA’s effectiveness vary widely and LUNA remains a controversial procedure. We conducted a single-blind, randomized controlled trial comparing LUNA with laparoscopy without pelvic denervation.

METHODS

The LUNA trial was a multicenter, prospective, randomized intervention trial with patient-blinded, patient-rated assessment of outcomes to evaluate LUNA. Ethics committee approval was obtained from the West Midlands Multicenter Research Ethics Committee (reference No. 99/7/03). Patients presenting to gynecology outpatient clinics with chronic pelvic pain (noncyclical pain, dysmenorrhea, or dyspareunia) lasting longer than 6 months, located within and below the anterior iliac crests, and who were undergoing diagnostic laparoscopy for differential diagnosis of chronic pelvic pain were invited to participate in our study.

Women were ineligible if they had previous LUNA, hysterectomy, or therapeutic procedures for, or diagnosis of, moderate to severe endometriosis or major pelvic inflammatory disease. Written informed consent was obtained before surgery. At laparoscopy, women were excluded if they were found to have more than minimal pathology (ie, American Fertility Society endometriosis score >5 or significant adhesions or serious adnexal pathology) or if bilateral LUNA was technically unfeasible. Intraoperatively, eligible patients were randomized via a telephone call to the Birmingham University Clinical Trials Unit, or through its Internet-based randomization service, to the LUNA group or the no LUNA group.

Randomization involved a computer minimization program to balance group allocations for site of pain, parity, self-reported sexual activity status, and presence or absence of minimal pathology. To avoid eligibility classification bias, treatment allocation was issued only after the surgeon had inspected the pelvis and ensured that the patient fulfilled all of the inclusion criteria and did not have any of the exclusion criteria.

Those allocated to the LUNA group had the procedure performed immediately by the same laparoscopic surgeon who had prior experience of the technique and who followed a common protocol. In a typical case, after inspection of the posterior leaf of the broad ligament to identify ureters and any pelvic venous congestion, the ablation was performed as close to the posterior aspect of the cervix as possible and continued for a minimum of 1 cm posterolaterally on either side with the intended aim of destroying the sensory nerve fibers and the secondary ganglia as they left the uterus and lie within the uterosacral ligaments.

Full or partial transaction of the ligaments was achieved bilaterally with laser or electrodiathermy, according to the surgeons’ preference. In centers in which surgeons used 2 additional ports to perform LUNA, a second 5-mm in-
cision was made in the patients in the no LUNA group through the skin in an area corresponding to where an additional port site was made. This approach of sham incisions has been used in a previous trial and was ethically justified to help avoid bias in the patient-rated assessment of a subjective outcome like pain. All women were asked at least 12 months after randomization whether they believed they had LUNA or no LUNA.

Baseline data were collected following consent and prior to laparoscopy. At 3 and 6 months following randomization and at 1, 2, 3 and 5 years, the same questionnaires were mailed to patients with a prepaid return envelope. Nonresponders were followed up through postal and/or telephone reminders or, if this failed, via their general practitioners.

The primary outcome of pain was rated using a 10-cm visual analogue scale (VAS), anchored at one end as no pain at all and at the other as the worst imaginable pain. The VAS ratings were obtained by measuring the distance from zero to that mark. This measurement is validated as a sensitive measure for large group comparisons.

The secondary outcome was health-related quality of life, which was measured using a generic instrument (EuroQoL EQ-5D [measured on a scale of −0.59 to 1 based on responses to 5 questions about life quality] and the EQ-VAS [measured on a 0-100 scale]). The need for additional treatments, resource usage, days off work, and complications of surgery were also recorded.

The sample size was powered to detect a small to medium effect of LUNA (0.3 SD effect size), equivalent to a difference between groups of 1.2 cm on the VAS, at a 2-sided α level of .05 and a β level of .20 (80% power), 175 women in each group (ie, 350 in total) were required. Allowing for a 20% loss to follow-up, the recruitment target was inflated to 420. Considering that existing research for chronic pelvic pain has shown substantial rates of loss to follow-up, recruitment continued until the end of the funding period when 487 women were included.

An independent data and safety monitoring board reviewed confidential interim analyses annually and recommended at each meeting continuing recruitment because the data were inconclusive.

All participants were analyzed in the group to which they were allocated using all available data and SAS statistical software version 9 (SAS Institute Inc, Cary, North Carolina). Baseline characteristics of the patients enrolled in the 2 groups were compared to ensure that randomization has produced comparable groups. Data for the various outcome measures were presented as means and mean differences over time with 95% confidence intervals (CIs).

<table>
<thead>
<tr>
<th>Table 1. Baseline Characteristics of Participants in the Laparoscopic Uterosacral Nerve Ablation (LUNA) Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUNA (n = 243)</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Age, mean (SD) [range], y</td>
</tr>
<tr>
<td>Clinical presentation</td>
</tr>
<tr>
<td>Nulliparous</td>
</tr>
<tr>
<td>Sexually active</td>
</tr>
<tr>
<td>Type of pain</td>
</tr>
<tr>
<td>Dysmenorrhea only</td>
</tr>
<tr>
<td>Nocyclical pain only</td>
</tr>
<tr>
<td>Dyspareunia only</td>
</tr>
<tr>
<td>All 3 types of pain</td>
</tr>
<tr>
<td>Central location of pain</td>
</tr>
<tr>
<td>Lapearoscopic findings</td>
</tr>
<tr>
<td>Any visible pathology</td>
</tr>
<tr>
<td>Adhesions</td>
</tr>
<tr>
<td>Pelvic inflammatory disease</td>
</tr>
<tr>
<td>Endometriosis</td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td>Minimal</td>
</tr>
<tr>
<td>Minimal, ablated</td>
</tr>
<tr>
<td>Pain medication</td>
</tr>
<tr>
<td>Analgesics</td>
</tr>
<tr>
<td>Antidepressants</td>
</tr>
<tr>
<td>Type of contraceptive</td>
</tr>
<tr>
<td>Combined oral</td>
</tr>
<tr>
<td>Mini-pill</td>
</tr>
<tr>
<td>Mirena coil</td>
</tr>
<tr>
<td>Not specified</td>
</tr>
<tr>
<td>Indication for other medication</td>
</tr>
<tr>
<td>Irritable bowel syndrome</td>
</tr>
<tr>
<td>Bladder pain</td>
</tr>
<tr>
<td>Urinary tract infection</td>
</tr>
<tr>
<td>Migraine</td>
</tr>
<tr>
<td>Asthma</td>
</tr>
<tr>
<td>Blood pressure</td>
</tr>
</tbody>
</table>

Values are expressed as number (percentage) unless otherwise indicated. Represents sexually active women only. There were missing data for 13 participants in the LUNA group and for 8 participants in the no LUNA group. There were missing data for 20 participants in the LUNA group and for 20 participants in the no LUNA group.
For the primary outcome, we analyzed data separately concerning the 3 types of pain (noncyclical pain, dysmenorrhea, and dyspareunia) and performed an analysis of the worst pain level experienced from any of these 3 types of pain. Comparisons between groups over time were undertaken using repeated-measures analyses, a statistically efficient approach that includes all of the follow-up data collated during the study, increasing power over analysis of data at individual time points. Pain scores at 12 months were compared using standard 2-sample t tests.

The principal analysis for the worst pain level experienced from any of the 3 types of pain was an intention-to-treat analysis using multiple imputation. To investigate the effect of missing data, the analyses of the individual types of pain at 12 months were repeated using the last observation carried forward method of imputation. All comparisons were 2-sided and were considered statistically significant if \( P < .05 \).

Subgroup analyses were chosen on the basis of anticipated variations in pain and potential benefit from LUNA, but were considered hypothesis generating. Prespecified subgroups were those used to stratify the randomization, namely site of pain (central, not central), presence or absence of minimal pathology for all types of pain, parity (nulliparous, multiparous), and whether women were sexually active or not.

**RESULTS**

Between February 1998 and December 2005, 487 women were randomized into the LUNA trial from 18 UK hospitals. A further 105 patients provided consent but were found at laparoscopy to have pathology that made them ineligible for randomization, or anatomy that precluded LUNA from being performed. No women in the control (no LUNA) group received LUNA, whereas 5 women in the LUNA group ultimately did not have LUNA performed bilaterally due to technical difficulties, but were analyzed in the LUNA group. 

**FIGURE 1** shows the trial profile. Baseline pain data were miss-

---

**Figure 2. Effect of Laparoscopic Uterosacral Nerve Ablation (LUNA) at 12 Months and at Each Time Point**

The graph on the right in each lettered part of the figure shows the difference in mean visual analogue scale (VAS) pain scores and 95% confidence intervals; values greater than 0 indicate that LUNA is a better therapy than no LUNA. The error bars indicate 95% confidence intervals.

*Indicates worst pain level experienced from any of the 3 types of pain analyzed (noncyclical pain, dysmenorrhea, and dyspareunia).
Table 2. Prespecified Subgroup Analyses Using Repeated-Measures Analysis

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Worst Pain Levela</th>
<th>Noncyclical Pain</th>
<th>Dysmenorrhea</th>
<th>Dyspareunia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Treatment Effect</td>
<td>(95% CI), cm</td>
<td>P Value</td>
<td>Treatment Effect</td>
</tr>
<tr>
<td>Parity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nulliparous</td>
<td>0.34 (−0.06 to 0.74)</td>
<td>0.50</td>
<td>−0.02 (−0.41 to 0.37)</td>
<td>0.60</td>
</tr>
<tr>
<td>Parous</td>
<td>−0.08 (−0.41 to 0.24)</td>
<td>0.30</td>
<td>−0.13 (−0.47 to 0.20)</td>
<td>0.20</td>
</tr>
<tr>
<td>Pathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>0.10 (−0.16 to 0.36)</td>
<td>0.20</td>
<td>−0.08 (−0.34 to 0.18)</td>
<td>0.20</td>
</tr>
<tr>
<td>Any minimal</td>
<td>0.19 (−0.81 to 1.18)</td>
<td>0.30</td>
<td>0.64 (−0.68 to 1.39)</td>
<td>0.20</td>
</tr>
<tr>
<td>Mid or minimal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometriosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central</td>
<td>−0.03 (0.31 to 0.30)</td>
<td>0.20</td>
<td>−0.15 (−0.46 to 0.16)</td>
<td>0.30</td>
</tr>
<tr>
<td>Not central</td>
<td>0.10 (−0.49 to 0.49)</td>
<td>0.30</td>
<td>0.01 (−0.50 to 0.51)</td>
<td>0.30</td>
</tr>
</tbody>
</table>

Abbreviation: CI, confidence interval.
aIndicates worst pain level experienced from any of the 3 types of pain analyzed (noncyclical pain, dysmenorrhea, and dyspareunia).
studies did not have strictly concealed randomization.

The LUNA trial is 4 times larger than any previously published trial evaluating neuroablation for chronic pelvic pain. It may be more reliable than any previous study of LUNA and also was designed to minimize bias, with concealment of allocation before randomization and blinded outcome assessment. Women were not told whether they received LUNA or not. Although the majority of women were not informed of their allocation, there is a suggestion that a small proportion were able to guess it correctly. If anything, however, this would likely enhance the apparent value of LUNA.

LUNA was adopted by many practitioners because afferent nerves from pelvic organs pass through the uterosacral ligament and it was thought that disruption of these would reduce the perceived pain. Lack of efficacy in our study and in prior studies provide evidence that the anatomical and physiological picture of chronic pelvic pain is more complicated. Anatomically, at least 5 pathways transmit signals from noxious stimuli in the pelvis. These nerve trunks vary in location and can intersect, with the potential for neuronal cross-talk. LUNA may obliterate some of the nerve fibers, but others are interwoven with the pelvic arteries and ureters.

Aggressive ablation more laterally risks damaging the ureter, so most procedures are compromised in their ability to achieve complete neurodestruction.

We followed up participants for longer than 6 months because laparoscopy may have a placebo effect for up to 3 to 6 months.36,37 We found no benefit for LUNA at any time point but found improvement in pain at 3 months for patients in both the LUNA group and the no LUNA group. This early pain reduction may be a placebo effect and attributable to the reassurance provided by the laparoscopic examination that there was no serious pathology. A comparison of diagnostic laparoscopy against no laparoscopy would be required to establish benefit. Alternatively, it could be a regression to the mean effect, with women more likely to undergo laparoscopy when their pain is at its worst, rather than at its average level.

This study has several limitations. We did not obtain follow-up data on all women but dropout rates were similar in each group and multiple imputation and last observation carried forward analyses produced near identical findings to those of the observed data. Given that we observed no effect of LUNA, the question arises whether this might be due to type II error (ie, inadequate statistical power). A clinically significant difference in pain has been defined as 2 points on a 10-point (cm) VAS for chronic pelvic pain36,37 and also for other types of pain,39 whereas our trial had the power to detect a 1.2-point difference at 12 months and even smaller differences over time. In every comparison, the 95% CIs around the mean difference in VAS scores between the groups were less than 1.2 points. Taking worst pain level experienced at 12 months as an example, the pain score was 0.02 cm lower in the LUNA group than in the no LUNA group and the 95% CI was 0.61 cm lower to 0.65 cm higher (ie, well below the level for clinically significant improvement).

In conclusion, among women with chronic pelvic pain, LUNA did not result in improvements in pain, dysmenorrhea, dyspareunia, pelvic pain or quality of life compared with laparoscopy without pelvic denervation.

Author Contributions: Ms Daniels had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors listed in the byline constitute the Trial Management Group who managed the day to day conduct of the trial.

Study concept and design: Daniels, Gray, Gupta, Lilford, Khan.

Acquisition of data: Daniels, Gray, Latthe, Gupta, Selman, Adey, Xiong, Champaneria, Khan.

Analysis and interpretation of data: Daniels, Gray, Hills, Buckley, Gupta, Lilford, Khan.

Drafting of the manuscript: Daniels, Gray, Buckley, Adey, Champaneria, Khan.

Critical revision of the manuscript for important intellectual content: Daniels, Gray, Hills, Latthe, Gupta, Selman, Xiong, Lilford, Khan.

Statistical analysis: Daniels, Gray, Hills, Buckley, Champaneria, Khan.

Obtained funding: Daniels, Gray, Gupta, Lilford, Khan.

Administrative, technical, or material support: Daniels, Gray, Latthe, Gupta, Selman, Adey, Xiong, Khan.

Study supervision: Daniels, Gray, Gupta, Lilford, Khan.

Financial Disclosures: None reported.

Funding/Support: The work was funded by the Wellbeing for Women charity grant CT371 and Birmingham Women’s Foundation NHS Trust Research and Development Committee, with additional support from the Birmingham Clinical Trials Unit, who are funded by the UK Department of Health. The LUNA trial was endorsed by the British Society of Gynaecological Endoscopy.

Role of Sponsor: The sponsor, under the UK Research and Governance Framework, was the University of Birmingham. Neither the funding sources nor the sponsor played a role in the design and conduct of the study; collection, management, analysis, or the interpretation of the data; and preparation, review, or approval of the manuscript.

LUNA Trial Coordination: Pallavi Latthe, MD, Tara Selman, PhD (clinical coordinators); Jane Daniels, MSc, Elizabeth Adey, BSc (trial managers); Robert Hills, PhD, Louise Hiller, PhD, Laura Buckley, PhD (statisticians); Tengbin Xiong, PhD, Rita Champaneria, MPhil (research associates); Rebecca Gair, MSc, Rebecca Powell, BSc, Leanne Lynch (trial administrators); Steve Gooding, MPhil, Nick Hillen, MPhil, Adrian Wilcockson, BSc (database programmers). All trial administrators and database programmers were at the Birmingham Clinical Trials Unit, University of Birmingham, England, at the time the research was conducted.

LUNA Trial Collaborators: Khalid S. Khan, MD, MSc, Pallavi Latthe, MD, Tara Selman, PhD, Janesh K. Gupta, MD, MSc, Christopher Mann, MD, T. Justin Clark, MD, John Newton, MD (Birmingham Women’s Hospital, Birmingham, England, n=241 patients); Patrick Chien, MBCHB, Maureen Macleod, BSc, RGN (Nineewells Hospital, Edinburgh, Scotland, n=2 patients); Mary Connor, MD, Andrew Baxter, MBCHB, Tom Farrell, MD, Carmel Bonner, RGN (Royal Hallamshire Hospital, Sheffield, England, n=39 patients); Vanessa Kay, MD, Wendy Crystal, RN, Maureen Pheely, RGN (Forth Park Hospital, Kirkaldy, Scotland, n=34 patients); Shin-Iri, MD (Birmingham Heartlands Hospital, Birmingham, England, n=22 patients); Linga Dwarkanathan, MBBS (City Hospital, Birmingham, England, n=14 patients); James Hollingworth, MD, Hon Est Howell, MD (Queens Hospital, University of Trent, England, n=9 patients); Kirk Chin, MBBS (Staffordshire General Hospital, England, n=8 patients); Joe Kabukoba, MD (Sandwell Hospital, West Bromwich, England, n=6 patients); Jagbir S. Samra, MD, Charles W. Cox, MBBS (New Cross Hospital, Wolverhampton, England, n=6 patients); Guy R. Fender, MD (Taunton and Somerset Hospital, England, n=6 patients); Khalid M. K. Ismail, PhD (City General Hospital, Stoke, England, n=3 patients); Stephen Keay, MBCHB (Walsgrave Hospital, Coventry, England, n=3 patients); Gabriel Awadz, MBBS (Derford Hospital, Plymouth, England, n=2 patients); Edward J. Shaxted, MBBS, Rebecca Hitchcock, RN, Jill Smith, RGN (Northampton General Hospital, Northampton, England, n=2 patients); Muhammad Zakaria, MBCHB, Nita Beecham, RN (Yeovil District Hospital, Yeovil, England, n=2 patients); William D. Phillips, MBCHB (Perth Royal Infirmary, Perth, Scotland; n=1 patient). Recruiting clinicians did not receive any financial incentive to take part in the LUNA trial.

Data and Safety Monitoring Board: Peter Brocklehurst, MSc, FRCoG (chair, University of Oxford); Joe Jordan, MD, FRCoG, (retired); Peter Burslem, MBBS, PhD (University of Aberdeen); Josie Sanderson, PhD (University of Birmingham).
Additional Contributions: We thank all of the women who participated in the trial for volunteering their help to improve the treatment of chronic pelvic pain.

REFERENCES


